GAITHERSBURG, Md., May 22 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced that Peter S. Greenleaf has joined the management team as senior vice president, marketing and sales. In this position, he is responsible for leading MedImmune’s global commercial organization and developing strategies to ensure the successful commercialization of the company’s current and future product portfolio.
“The addition of Peter to our team is the capstone of a series of steps taken to strengthen our commercial organization and to prepare for the opportunities that lie ahead,” said David M. Mott, chief executive officer and president. “Peter is a high-energy professional who brings both marketing and sales management experience as well as an entrepreneurial biotechnology background, which he will apply to leading our more than 550 professionals in the marketing and sales organization. Peter’s initial focus will be on ensuring a successful 2006-2007 season for Synagis(R) (palivizumab). He will concurrently lead the preparations for the potential launches of next- generation FluMist(R) (Influenza Virus Vaccine Live, Intranasal) in 2007 and MedImmune’s next-generation anti-RSV monoclonal antibody, Numax(TM), in 2008. Peter will also focus on continuing to build our commercial capabilities and portfolio in the oncology marketplace where we currently sell Ethyol(R) (amifostine).”
Prior to joining MedImmune, Mr. Greenleaf was a vice president for Centocor, Inc., with responsibility for the company’s gastroenterology commercial operation including sales, marketing, strategic planning and business development. He joined Centocor’s cardiovascular division in 1998 and later moved into the immunology business, holding a number of positions with increasing responsibility in sales and marketing. Previously, he was employed in sales and marketing capacities with Boehringer Mannheim Corporation and US Healthcare, Inc. Mr. Greenleaf holds a bachelor’s degree from Western Connecticut State University and a master’s in business administration from St. Joseph’s University.
Mr. Greenleaf is the sixth recent senior-level appointment on the commercial side of MedImmune’s business, including R. Michael Smullen to senior vice president, sales; Frank D. Czworka, Jr., to vice president, sales, infectious disease; John J. Trizzino to vice president, trade and distribution; Mark C. Twyman to vice president and general manager, vaccines; and Douglas B. Willner to vice president, sales training.
About MedImmune, Inc.
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious disease, cancer and inflammatory diseases. With more than 2,300 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.
MedImmune, Inc.
CONTACT: Media: Kate Barrett, +1-301-398-4320, or Investors: Peter Vozzo,+1-301-398-4358, both of MedImmune, Inc.
Web site: http://www.medimmune.com/
